Abstract 910P
Background
Parotid mucoepidermoid carcinoma (P-MEC) is a major histopathological subtype of salivary gland cancer, characterized by heterogeneity and complexity. Traditional clinical models and treatment plans are limited in providing personalized treatment recommendations and clinical management. This study aims to develop a machine learning-based prognostic model to improve survival rate prediction accuracy for P-MEC patients.
Methods
We used SEER database data (2004-2015) for 882 postoperative P-MEC patients. Single-factor Cox regression and four machine learning algorithms (Random Forest, LASSO, XGBoost, Best Subset Regression) were employed for variable selection and importance evaluation. The optimal variable selection model was determined using stepwise backward regression, AIC, and AUC. Bootstrap resampling was applied for internal validation.The model's prediction accuracy was assessed through C-index, ROC curve, and calibration curve. The clinical utility of the model was evaluated via DCA.
Results
The 3-, 5-, and 10-year OS rates for postoperative P-MEC patients were 0.887, 0.841, and 0.753. XGBoost, BSR, and LASSO demonstrated good predictive performance in variable selection and identified 7 independent prognostic factors: age, pathological grade, T stage, N stage, radiation therapy, chemotherapy, and marital status. A nomogram was developed based on the identified predictive variables. Internal validation with 1000 bootstrap resamples yielded consistent results for C-index (3-year, 0.841, 95%CI=0.839-0.844; 5-year, 0.842, 95%CI=0.840-0.845) and AUC (3-year, 0.858, 95%CI=0.856-0.860; 5-year, 0.872, 95%CI=0.870-0.875). The calibration plot indicated good prediction fit.
Conclusions
This study identified age, pathological grade, T stage, N stage, radiation therapy, chemotherapy, and marital status as independent prognostic factors in postoperative P-MEC patients. Machine learning algorithms outperformed traditional analysis methods in variable selection, predictive performance, and variable importance visualization. The developed machine learning-based nomogram offers high accuracy, robust calibration, and clinical application value for postoperative P-MEC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
942P - Response to salvage chemotherapy with paclitaxel +/- cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster session 12
944TiP - Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial
Presenter: Bálint Tamaskovics
Session: Poster session 12
1089P - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Presenter: Paolo Ascierto
Session: Poster session 12
1090P - Outcome impact of time from complete resection to start of adjuvant immunotherapy in stage III-IV melanoma patients
Presenter: Sergio Martinez Recio
Session: Poster session 12
1092P - Adjuvant treatment with anti-PD-1 in acral melanoma patients: A nationwide study
Presenter: Manja Bloem
Session: Poster session 12
1093P - Neoadjuvant (NeoAd) intratumoral (IT) TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab (NIVO) for patients (pts) with operable locoregionally advanced melanoma
Presenter: Ahmad Tarhini
Session: Poster session 12
1094P - Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
Presenter: Elizabeth Burton
Session: Poster session 12
1095P - Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Presenter: Irene Reijers
Session: Poster session 12